A fatal case of immune hyperhemolysis with bone marrow necrosis in a patient with sickle cell disease

Hematology Reports

Volumn 9, Issue 1, 2017, Pages 8-11

  Karatin, Matthew S ^a,b   Singavi, Arun ^b   Johnson, Susan T ^a   Field, Joshua J ^a,b  

^a BLOOD RESEARCH INSTITUTE   (United States)

^b MEDICAL COLLEGE OF WISCONSIN   (United States)

Author keywords

Bone marrow necrosis; Hyperhemolysis syndrome; Sickle cell disease

Indexed keywords

AUTOANTIBODY; IMMUNOGLOBULIN; PREDNISONE; ROMIPLOSTIM;

ADULT; ALLOIMMUNIZATION; ANTIBODY BLOOD LEVEL; ARTICLE; BONE MARROW BIOPSY; BONE MARROW NECROSIS; CASE REPORT; CLINICAL FEATURE; DISEASE ASSOCIATION; DISEASE SEVERITY; DRUG EFFECT; ERYTHROCYTE TRANSFUSION; FATALITY; FEMALE; HEMOLYSIS; HUMAN; HUMAN TISSUE; IMMUNE HYPERHEMOLYSIS; MIDDLE AGED; PHYSICAL EXAMINATION; RETICULOCYTOPENIA; SICKLE CELL ANEMIA; THROMBOCYTOPENIA;

EID: 85016018888     PISSN: 20388322     EISSN: 20388330     Source Type: Journal    
DOI: 10.4081/hr.2017.6934     Document Type: Article

References (21)

1. Rees DC, Williams TN, Gladwin MT. Sickle-cell disease. Lancet 2010; 376: 2018-31.
2. Yawn BP, Buchanan GR, Afenyi-Annan AN, et al. Management of sickle cell disease. Summary of the 2014 evidence-based report by expert panel members. JAMA 2014; 312: 1033-48.
3. Chou ST. Transfusion therapy for sickle cell disease: a balancing act. Hematology Am Soc Hematol Educ Program 2013; 2013: 439-46.
4. Talano JA, Hillery CA, Gottschall JL, et al. Delayed hemolytic transfusion reaction/ hyperhemolysis syndrome in children with sickle cell disease. Pediatrics 2003; 111: e661-5.
5. Aygun B, Padmanabhan S, Paley C, Chandrasekaran V. Clinical significance of RBC alloantibodies and autoantibodies in sickle cell patients who received transfusions. Transfusion 2002; 42: 37-43.
6. Win N. Hyperhemolysis syndrome in sickle cell disease. Expert Rev Hematol 2009; 2: 111-5.
7. de Montalembert M, Dumont MD, Heilbronner C, et al. Delayed hemolytic transfusion reaction in children with sickle cell disease. Haematologica 2011; 96: 801-7.
8. Scheunemann LP, Ataga KI. Delayed hemolytic transfusion reaction in sickle cell disease. Am J Med Sci 2010; 339: 266-9.
9. Reid ME, Lomas-Francis C, Olsson ML. The blood group antigen facts book. 3rd ed. London: Elsevier; 2012.
10. Garratty G. What do we mean by hyperhaemolysis and what is the cause? Transfus Med 2012; 22: 77-9.
11. King KE, Shirey RS, Lankiewicz MW, et al. Delayed hemolytic transfusion reactions in sickle cell disease: simultaneous destruction of recipients’ red cells. Transfusion 1997; 37: 376-81.
12. Ahrens N, Pruss A, Kähne A, et al. Coexistence of autoantibodies and alloantibodies to red blood cells due to blood transfusion. Transfusion 2007; 47: 813-6.
13. Win N, New H, Lee E, de la Fuente J. Hyperhemolysis syndrome in sickle cell disease: case report (recurrent episode) and literature review. Transfusion 2008; 48: 1231-8.
14. Chadebech P, Habibi A, Nzouakou R, et al. Delayed hemolytic transfusion reaction in sickle cell disease patients: evidence of an emerging syndrome with suicidal red blood cell death. Transfusion 2009; 49: 1785-92.
15. Barcellini W, Fattizzo B, Zaninoni A. Clinical heterogeneity and predictors of outcome in primary autoimmune hemolytic anemia: a GIMEMA study of 308 patients. Blood 2014; 124: 2930-6.
16. Ibanez C, Habibi A, Mekontso-Dessap A, et al. Anti-HI can cause a severe delayed hemolytic transfusion reaction with hyperhemolysis in sickle cell disease patients. Transfusion 2016; 56; 1828-33.
17. Wool GD, Deucher A. Bone marrow necrosis: ten-year retrospective review of bone marrow biopsy specimens. Am J Clin Pathol 2015; 143: 201-13.
18. Ataga KI, Orringer EP. Bone marrow necrosis in sickle cell disease: a description of three cases and review of the literature. Am J Med Sci 2000; 320: 342-7.
19. Charache S, Page DL. Infarction of the bone marrow in sickle cell disorders. Ann Intern Med 1967; 67: 1195-2000.
20. Tsitsikas DA, Gallinella G, Patel S, et al. Bone marrow necrosis and fat embolism syndrome in sickle cell disease: increased susceptibility of patients with non-SS genotypes and a possible association with human parvovirus B19 infection. Blood Rev 2014; 28: 23-30.
21. Bachmeyer C, Maury J, Parrot A, et al. Rituximab as an effective treatment of hyperhemolysis syndrome in sickle cell anemia. Am J Hematol 2010; 85: 91-2.